CureGene
CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026
CG-0416 combined with a reduced-dose GLP-1 receptor agonist produced greater weight loss, and slower weight regain after the agonist was stopped…
Company newsroom
2 releases
CG-0416 combined with a reduced-dose GLP-1 receptor agonist produced greater weight loss, and slower weight regain after the agonist was stopped…
CureGene Presents Evategrel China–US PK/PD and Food-Effect Data at AHA 2026 SHANGHAI, Nov. 8, 2026 — Clopidogrel does not work the same way in every…